Literature DB >> 25275044

The role of functional polymorphisms of cyclooxygenase 2 in renal cell carcinoma.

Wen-Shin Chang1, Cheng-Hsi Liao2, Chia-En Miao3, Hsi-Chin Wu4, Lin-Lin Hou3, Chieh-Lun Hsiao3, Hong-Xue Ji3, Chia-Wen Tsai3, Da-Tian Bau5.   

Abstract

Renal cell carcinoma (RCC) accounts for about 3% of all cancer-related mortalities worldwide and the risk factors for the development of RCC have not yet been fully elucidated. Mounting evidence shows that overexpression of cyclo-oxygenase 2 (COX2) is commonly found in malignant tumors, including RCC. However, the contribution of genotypic variations of COX2 to RCC has not been studied. We hypothesized that variants of the COX2 gene are associated with risk of susceptibility to RCC in Taiwan. In this hospital-based case-control study, 92 patients with RCC and 580 age- and gender-matched cancer-free controls were recruited and the associations of COX2 A-1195G, G-765C, T+8473C, intron 1, intron 5, and intron 6 polymorphisms with RCC risk were examined in this Taiwanese population. The results showed that compared to the wild-type GG genotype, the CG genotype for COX2 G-765C was significantly associated with a lower risk of RCC (odds ratio=0.34, 95% confidence interval=0.15-0.80, p=0.0082). For other polymorphic sites, no obvious associations were found. There was also an obvious association of COX2 G765C genotype with reduced RCC risk among those without family cancer history (p=0.0331). These evidence indicated that COX2 G-765C genotype involved in the etiology of RCC and may serve as a novel genetic marker for susceptibility of RCC. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  COX2; Taiwan; genotype; polymorphism; renal cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25275044

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Genetic association of cyclooxygenase-2 gene polymorphisms with Parkinson's disease susceptibility in Chinese Han population.

Authors:  Yi Dai; Yuquan Wu; Yansheng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  The Contribution of MMP-7 Promoter Polymorphisms in Renal Cell Carcinoma.

Authors:  Cheng-Hsi Liao; Wen-Shin Chang; Pei-Shin Hu; Hsi-Chin Wu; Shih-Wei Hsu; Yen-Fang Liu; Shih-Ping Liu; Huey-Shan Hung; DA-Tian Bau; Chia-Wen Tsai
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 3.  Soy and breast cancer: focus on angiogenesis.

Authors:  Lenka Varinska; Peter Gal; Gabriela Mojzisova; Ladislav Mirossay; Jan Mojzis
Journal:  Int J Mol Sci       Date:  2015-05-22       Impact factor: 5.923

4.  The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature.

Authors:  Jinling Bi; Haiyuan Liu; Yong Huang
Journal:  Int Med Case Rep J       Date:  2017-07-04

5.  Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism.

Authors:  Jianchang Li; Mingning Qiu; Lieqian Chen; Lei Liu; Guobin Tan; Jianjun Liu
Journal:  Oncol Lett       Date:  2016-12-20       Impact factor: 2.967

6.  Association between GSTP1 Ile105Val polymorphism and urinary system cancer risk: evidence from 51 studies.

Authors:  Yixiang Zhang; Yeqing Yuan; Yufang Chen; Zhao Wang; Fangfang Li; Qingsong Zhao
Journal:  Onco Targets Ther       Date:  2016-06-15       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.